# Cure Pharmaceutical Holding Corp. (CURR)

**Exchange:** NASDAQ  
**Sector:** Technology  
**Market cap:** $118M  
**Price:** $3.08 (+5.12%)

> Cure Pharmaceutical Holding Corp. is a biopharmaceutical company focused on the development and commercialization of innovative drug delivery systems. It aims to improve patient adherence and experience by providing new methods for drug delivery, such as oral thin films and transdermal systems. Cure Pharmaceutical's technologies are designed to enhance the bioavailability, efficacy, and safety of existing pharmaceutical compounds while also providing a platform for new drug formulations. This plays a vital role in several therapeutic areas, including pain management, oncology, and central nervous system disorders. By leveraging cutting-edge technology and partnerships within the pharmaceutical industry, Cure Pharmaceutical Holding Corp. contributes to the advancement of personalized and precision medicine, addressing unmet medical needs and broadening the spectrum of delivery options in healthcare markets.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2024 | $46M | $15M | -$27M | -$39M | — |
| 2023 | $53M | $17M | -$7M | -$15M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2024 | $105M | $146M | -$66M | $64M | $4M |
| 2023 | $141M | $178M | -$63M | $49M | $3M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2024 | $3M | $576,674 | $3M |
| 2023 | -$15M | $291,856 | -$16M |
| 2022 | -$756,716 | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/CURR)